Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial-Reference-Cited by-同舟云学术

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Published:2013-05 Issue:6 Volume:14 Page:552-562
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Motzer Robert J,Escudier Bernard,Tomczak Piotr,Hutson Thomas E,Michaelson M Dror,Negrier Sylvie,Oudard Stephane,Gore Martin E,Tarazi Jamal,Hariharan Subramanian,Chen Connie,Rosbrook Brad,Kim Sinil,Rini Brian I

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3;Hu-Lowe;Clin Cancer Res,2008

2. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study;Rixe;Lancet Oncol,2007

3. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma;Rini;J Clin Oncol,2009

4. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma;Tomita;Eur J Cancer,2011

5. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011

Cited by 652 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology;Current Oncology;2024-08-22

2. Renal cell carcinoma;The Lancet;2024-08

3. Renal cancer: signaling pathways and advances in targeted therapies;MedComm;2024-08

4. Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma—Systematic Literature Review of Clinical and Real-World Evidence;Cancers;2024-07-30

5. Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population;Future Oncology;2024-06-23